




References

REFERENCES

Abdalla FZ., Aly MM. and El-Bediewy AM. (1979):

An immunologic study of lung cancer using an immunofluorescent technique.

Egy. J. Ches. Dis. & Tuber, 22: 117.

Abdalla FZ. and Ghoneim MA. (1978):

The problem of bronchogenic carcinoma in Egypt.

Egy. J. Ches. Dis. & Tuber., 21(1): 49.

Aisner, SC. (1985):

The pathology of lung cancer. In: Aisner J. ed.

Lung cancer, p.:1-24, Churchill Livingstone, New York.

Akoun G., Scarna M. and Herman D. (1985):

Serum neuron- specific enolase: a marker for disease extent and response to therapy for small cell lung cancer.

Chest, 87: 39.

Altmannsberger M. (1982):

Diagnosis of human childhood rhabdomyosarcoma by antibodies to desmin the structural protein of muscle-specific intermediate filaments.

Virchows Arch. B., 39: 203.

References

- Anderson JR. (1987):
Tumors of the bronchi, lung and pleura. In: Muir's
textbook of pathology. 12th ed., 16.65-72, ELBS, London.
- Arakawa M., Zeltzer P. and Evans A. (1985):
Serum neuron-specific enolase in children with
neuroblastoma.
Cancer, 57: 230.
- Bakemeier RF., Krachov SF. and Rubin PP. (1983):
Cancer of the major digestive glands: Pancreas, liver, bile
ducts, and gall bladder. In: Rubin P.
Clinical oncology. American Cancer Society Chicago, 178.
- Bains MS. (1991):
Surgical treatment of lung cancer.
Chest, 100(3): 826.
- Bates SE. (1991):
Clinical applications of serum tumor markers.
Ann. Intern. Med., 115: 623.

Bates S. and Longo L. (1985);

Tumor markers: value and limitation in the management of cancer patients.

Cancer Treat. Rev., 12: 163.

Berlin N. (1981):

Tumor markers in cancer prevention and detection.

Cancer, 47: 1115.

Bignami A. (1980):

Glial fibrillary acidic protein (GFA) in normal neural cells and in pathological conditions, advances in cellular neurobiology.

Vol. I., edited by S. Federoff, L. Hertz, New York, Academic Press, p.: 285.

Birkmayer G and Klavins J. (1990):

Classification of tumor markers.

The second international conference of the Egyptian society of tumor markers oncology, P. 46 (Meeting abstract).

Bjorklund B. (1992):

Tumor markers TPA, TPA-S and cytokeratins.

Tumor Diagn. U. Ther., 13: 78.

Blijenberg BG. (1994):

Evaluation of a new tumor marker in patients with non-small cell lung cancer: CYFRA 21-1.

Br. J. Cancer, 69: 525.

Bosch FX. (1993):

Etiology. In: Hossfeld D.K. and Sherman C.D. (eds).

Manual of clinical oncology. 5th ed., p.:45-71, Springer-Verlag, New York.

Bosch FX. and Coleman MP. (1993):

Descriptive epidemiology. In: Hossfeld D.K. and sherman C.D. (eds). Manual of Clinical Oncology, 5th ed., p.:31-44, Springer Verlag, New York.

Bourke, GJ.; Dally, LE. and McGilvray, J. (1985):

Interpretation and Uses of Medical Statistics.

Third edition. Blackwell Scientific Publications, Oxford, London, Edinburgh, Boston, Palo Alto, Melbourne. P.:50-75

Brew's RA (1985):

Carcinoma of the bronchus. In: Lecture notes on respiratory diseases. 3rd ed., p.:244-61, Blackwell Scientific Publications, Oxford.

- Bruderman I. (1994):
Bronchogenic carcinoma. In: Baum G.L. and Wolinsky E
(eds), Text book of pulmonary diseases. Fifth edition,
p:1345-91, Little, Brown and Company, Boston.
- Buccheri GF. (1987):
Tumor markers in bronchogenic carcinoma: superiority of
tissue polypeptide antigen to carcinoembryonic antigen and
carbohydrate antigenic determinant 19-9.
Cancer, 60: 42.
- Carney DN. and Leu LD. (1988):
Lung cancer biology.
Semin. Oncol., 15: 199.
- Carney DN., Zweig MH. and Ihde DC. (1984):
Elevated serum creatine kinase-BB in patients with small
cell lung cancer.
Cancer Res., 44: 5399.
- Carter D., Marsh BR. and Baker RR. (1976):
Relationship of morphology to clinical presentation in ten
cases of early squamous cell carcinoma of the lung.
Cancer, 37: 1389.
-

References

- Charlton A. (1994):
Tobacco and lung cancer. In Thatcher N. and Spiro S.
(eds): New perspectives in lung cancer.
1st ed., p.: 1-17, BMJ Publishing Group, London.
- Clark DW. and MacMahon B. (1981):
Lung cancer. In: Preventive and community medicine.
2nd ed., p.:454-57, Little Brown and Company, Boston.
- Coombes R., Powles J. and Ford H. (1987):
Biochemical marker in human breast cancers.
Lancet, I.: 132.
- Davis S. and May P. (1982):
Infrequent elevation of plasma ACTH in patients with
bronchogenic carcinoma.
Am. J. Med. Sci., 283:2.
- Debus ER., Moll WW. and Franke K. (1984):
Immunohistochemical distinction of human carcinomas by
cytokeratin typing with monoclonal antibodies.
Am. J. Pathol., 114: 121.

- Dewys W.D., Killen J.Y. and Nelson RA (1983):
The paraneoplastic syndromes. In: Rubin P., Bakemeier
R.F., Krachov S.K. eds..
Clinical oncology, A multidisciplinary approach. 6th ed.
American Cancer Society Chicago, 112.
- Ebert W., Dinemann H., and Fateh-Moghadam A. (1994):
Cytokeratin 19 fragment CYFRA 21-1 compared with
carcinoembryonic antigen, squamous cell carcinoma antigen
and neuron-specific enolase in lung cancer.
Eur. J. Clin. Chem. Clin. Biochem., 32: 189.
- El-Zayat A. (1979):
Postgraduate medicine.
1st edition. El-Naser Bookshop, p.: 270.
- Fishman AP. (1988):
Cancer of the lung. In: pulmonary diseases and disorders.
2nd ed., p.:1885-2032, McGraw Hill Book Company, New
York.
- Flenley DC. (1990):
Pulmonary tumors. In: Respiratory medicine. 2nd ed., p.:239-
64, Bauller Tindall, London.
-

- Gardner RC., Feinerman AE. and Kantrowitz PA. (1978):
Serial carcinoembryonic antigen (CEA) blood levels in
patients with ulcerative colitis.
Am J. Dig. Dis., 23: 129.
- Geiger B. (1987):
Intermediate filament: looking for a function.
Nature, 29: 392.
- Gerwin B.I., Spillar E. and Ferrester K. (1992):
Mutant P53 can induce tumorigenic conversion of human
bronchial epithelial cells and reduce their responsiveness to
a negative growth factor.
Proc. Natl. Acad. Sci. U.S.A., 9(7): 2759.
- Go V.L. (1976):
Carcinoembryonic antigen: Clinical application.
Cancer, 37: 562.
- Hande K.R. and Desprez R.M. (1984):
Current perspective in small cell lung cancer.
Chest, 85(5): 669.

References

- Hansen HJ., Synder LJ. and Miller E. (1974):
Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer.
J. Hum. Path., 5: 139.
- Hansen M. and Pedersen A.G. (1986):
Tumor markers in patients with lung cancer.
Chest, 89(4): 219.
- Hanukoglu I., and Fuchs E. (1982):
The cDNA sequence of a human epidermal keratin: divergence of sequence but conservation of structure among intermediate filaments.
Cell, 31: 243.
- Heimburger DC., Alexander CB. and Krumdieck CL. (1988):
Effect of folate and vitamin B₁₂ in squamous metaplasia of smokers.
JAMA, 259: 1525.

Heitzman ER. (1986):

The role of computed tomography in the diagnosis and management of lung cancer.

Chest, 89(4): 237.

Holland JF. and Frei E. (1982):

Respiratory tract cancer. In; Cancer medicine.

2nd ed., p.:1709-39, Lee & Febiger, Philadelphia.

Hopkin JM. and Evans JF. (1979):

Diseases of the chest.

4th ed. W.B. Saunders Company, p.: 472.

Howard P. (1991):

Lung tumors. In: respiratory medicine.

1st ed., p.;156-74, Edward Arnold, London.

Huang MS. (1997):

Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumor markers in bronchogenic carcinoma. Respiratory Medicine, 91 : 135.

Hussein DA. (1994):

Clinical and histochemical study for diagnosis and treatment of lung cancer. M.D. Thesis (Medical oncology). National Cancer Institute. Cairo University.

International Agency for Research on Cancer (1996):

Monograph on the evaluation of the carcinogenic risk of chemicals to World Health Organization, Geneva.

Janerich DT., Thompson WD. and Varela LR. (1990):

Lung cancer and exposure to tobacco smoke in the household.

N. Engl. J. Med., 323: 632.

Japues G, Bepler G and Havemann K. (1988):

Prognostic value of pre-treatment carcinoembryonic antigen, neuron specific enolase and creatine kinase-BB levels in sera of patients with small cell lung cancer.

Cancer, 62(1): 125.

Jhonson BE. and Kelley MJ. (1993):

Overview of genetic and molecular events in the pathogenesis of lung cancer.

Chest, 103(1): 15.

Kalemkerian G.P. (1994):

Biology of lung cancer.

Current opinion in oncology, 6(2): 147.

Kato H. (1982):

Value of tumor- antigen (TA-4) of squamous cell carcinoma
in predicting the extent of cervical cancer.

Cancer, 50: 1294.

Khalifa A., Bolos M., and Tageldin MA. (1983):

Immunological response and biochemical changes in cancer
lung. The 6th annual Ain Shams Medical Congress.

Khoo SK., Warner NL. and MacKay IR. (1973):

Carcinoembryonic antigen activity of tissue extracts: A
qualitative study of malignant and benign neoplasms,
cirrhotic liver, normal adult and fetal organs.

Int. J. Cancer, 11: 681.

Kissane JM. and Anderson WAD. (1985):

Lung tumors. In: Anderson's pathology. 8th ed., p.:917-37,
The C.V. Mosby Company, St. Louis.

Klavins DV. (1983):

Advances in biological markers for cancer.

Ann. of Clin. Lab. Sci., 13: 275.

Krischke W., Niederle N. and Hirche H. (1988):

Is there any clinical relevance of serial determinations of serum carcinoembryonic antigen in small cell lung cancer patients?

Cancer, 62: 1348.

Laberge F., Fritsche H. and Carr D. (1987):

Use of carcinoembryonic antigen in small cell lung cancer.

Prognostic value and relation to the clinical course.

Cancer, 59: 2047.

LeRoux BT. (1986):

Small cell lung cancer.

Am. Rev. Respir. Dis., 134: 593.

Lockey JE. (1994):

Radon and man made vitreous fibers.

Journal of Allergy and Clinical Immunology, 94(2): 310.

Luning M., Pruss RM. and Mirsky R. (1980):

All classes of intermediate filaments share a common antigenic determinant defined by a monoclonal antibody.
Cell, 27: 419.

Lurie BB., Lowenstein MS. and Zamcheck N. (1975):

Elevated carcinoembryonic antigen levels and biliary tract obstruction.
J. Am. Med. Assoc., 233: 326.

Luster W., Gropp G. and Sostmann H. (1982):

Demonstration of immunoreactive calcitonin in sera and tissues of lung cancer patients.
Eur. J. Cancer Clin. Oncol., 18: 1275.

Macchia V., Mariano A. and Copp A. (1987):

Tumor markers and lung cancer.
Int. J. Biol. Markers, 2(3): 151.

Maruo T., Shibata K. and Kimura A. (1985):

Tumor associated antigen, TA-4 in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix.
Cancer, 56: 302.

McDufie H.H. (1991):

Atopy and primary lung cancer.

Chest, 99: 404.

Michael L., Vanlau F. and Edward P. (1985):

Biochemical classification of tumor markers.

Clin. Chem., 7: 495.

Miller DF. (1992):

Dimensions of community health. 3rd ed., p.:242, Win C

Brown Publishers, U.S.A.

Mizushima Y., Tsuji H. and Yano S. (1991):

Clinical evaluation of five tumor marker assays in patients
with lung cancer.

Anticancer Res., 11: 91.

Moll R., Franke WW. and Schiller DL. (1982):

The catalog of human cytokeratins: patterns of expression
in normal epithelia, tumors and cultured cells.

Cell, 31: 11.

Mountain CF. (1986):

A new international staging system for lung cancer.
Chest, 89(4): 225.

Muers MF. (1994):

How much investigation? In: Thatcher N. and Spire s (ed.).
New perspectives in lung cancer. 1st ed., p.:77-103, BMJ
Publishing Group, London.

Mulshine JL., Trestan AM., and Show GL. (1993):

Initiators and promoters of lung cancer.
Chest, 10-3 (1 Suppl.), p.:4S-11S.

Naoko M. (1988):

Availability of tumor antigen 4 as a marker of squamous
cell carcinoma of the lung and other organs.
Cancer, 62: 730.

Neville A. and Cooper E. (1986):

Biochemical monitoring of cancer.
Ann. Clin. Biochem., 13: 283.

Orphanidon D., Dimakon K. and Williams P. (1994):

Usefulness of CYFRA 21-1 and SCC determinations in serum and bronchial washing.

Eur. Respir. J., 7 (Suppl. 18): 55.

Osborn M., Geisler N., and Weber K. (1982):

Intermediate filaments. Cold Spring Harbor Symposium

Quant Biol., 46: 413.

Osborne DR., Korobkin M. and Ravin CE. (1982):

Comparison of plain radiography, conventional tomography and computed tomography in detecting intrathoracic lymph node metastasis from lung carcinoma.

Radiology, 142: 157.

Parkin DM. (1993):

Estimation of the worldwide incidence of eighteen major cancer in 1985.

Int. J. Cancer., 54: 549.

Petruzzelli S. and Giuntini C. (1994):

Host factors in lung carcinogenesis.

Monaldi Archives for Chest Diseases, 49(3): 235.

Plebani M., Basso D. and Navaglia F. (1995):

Clinical evaluation of seven tumor markers in lung cancer
diagnosis: can any combination improve the results?
Br. J. of Cancer, 72: 170.

Pohl A. (1987):

Surveillance of cancer patients with tumor markers.
J. Tumor Markers Oncology, 2(1): 6.

Pohl A. (1990):

Tumor markers: potential and limits of their application.
The Second International Conference of the Egyptian
Society of Tumor Markers Oncology, P.96 (Meeting
Abstract).

Pujol J, Grenier J. and Daver A. (1993):

Serum fragments of cytokeratin subunit 19 measured by
CYFRA 21-1 immunoradiometric assay as a marker of lung
cancer.
Cancer Res., 53: 16.

Robinson B., Marsh B. and Coster D. (1979):

Development of carcinoma of the lung as reflected in exofoliated cells.

Cancer, 33: 256.

Ronquist G. (1983):

A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms.

Cancer, 52: 1679.

Rowlands DT. (1986):

Diseases of the respiratory system. In: Human pathology.

1st ed., p.:271-74, McMillan Publishing company, New York.

Salgia R. and Skarin A. (1998):

Molecular abnormalities in lung cancer.

J. Clin. Oncol., 16 (3): 1207.

Samet J.M. (1993):

The epidemiology of lung cancer.

Chest, 103(1): 205.

Sardi A., Nieroda CA. and Minton JP. (1990):

Carcinoembryonic antigen directed multiple surgical procedures for recurrent colon cancer confined to the liver.
Am. J. Surg., 56: 255.

Seaton A., Seaton D. and Leitch AG. (1989):

Cancer of the lung. In: Crofton and Douglas's respiratory disease. 4th ed., p.:912-74, Blackwell Scientific Publications, Oxford.

Sell S. (1990):

Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers.
Clinics in Laboratory Medicine, 10(1):10.

Shapshay SM. (1986):

Value of bronchoscopy in clinical practice. A review of 1109 examination.
Chest, 89(4): 333.

- Souquet P.J., Boissel JP. and Williams J. (1993):
Polychemotherapy in advanced non-small cell lung cancer: a
meta-analysis.
Lancet, 342: 19.
- Stasiak P., Leigh P. and Lane E. (1989):
Keratin 19: Predicted amino acid sequence and broad tissue
distribution suggests it evolved from keratinocyte keratins.
J. invest. Dermatol., 92: 707.
- Steiber P., Hasholzner U. and Bodenmuller H. (1993):
CYFRA 21-1: a new marker in lung cancer.
Cancer, 72: 707.
- Tredmel J., Stuker I., Miguad I., et al. (1991):
Detection of bronchial cancer, realities and perspectives.
Rev. Mal. Respir., 8(6): 543.
- Van der Gaast A., Schoenmaker C., and Splinter T. (1994):
Evaluation of a new tumor marker in patients with non-
small cell lung cancer: CYFRA 21-1.
Br. J. Cancer, 69: 525.

Weinberger SE. (1986):

Lung cancer: Etiologic, pathologic and clinical aspects. In:
Principles of pulmonary medicine. 1st ed., p.:226-247, W.B.
Saunders Company, Philadelphia.